Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.

ABSTRACT:

Purpose

The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.

Materials and methods

Patients were intraoperatively randomly assigned to carboplatin HIPEC (800 mg/m² for 90 minutes) or no HIPEC, followed by five or six cycles of postoperative IV carboplatin-based chemotherapy, respectively. Based on a binomial single-stage pick-the-winner design, an arm was considered winner if ≥ 17 of 49 patients were without disease progression at 24 months post-surgery. Secondary objectives included postoperative toxicity and HIPEC pharmacokinetics.

Results

Of 98 patients, 49 (50%) received HIPEC. Complete gross resection was achieved in 82%

SUBMITTER: Zivanovic O 

PROVIDER: S-EPMC8330970 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature